STSA Pengajuan SEC - Satsuma Pharmaceuticals Inc- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	549300CFJJ7QFB1VAD84
CIK	1692830

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Satsuma Pharmaceuticals Inc

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

June 20, 2023	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-39041 Satsuma Pharmaceuticals, Inc. (Exact name of registrant as
June 13, 2023	SC 13G/A	STSA / Satsuma Pharmaceuticals Inc / BML Investment Partners, L.P. - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 80405P107 (CUSIP Number) June 08, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box
June 12, 2023	SC 13D/A	STSA / Satsuma Pharmaceuticals Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 80405P107 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Telephone: 617.778.2512 Attn:
June 8, 2023	EX-99.(D)(9)	CONTINGENT VALUE RIGHTS AGREEMENT SHIN NIPPON BIOMEDICAL LABORATORIES, LTD., AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, as the Rights Agent Dated as of June 6, 2023 EX-99.(d)(9) Exhibit (d)(9) Execution Version CONTINGENT VALUE RIGHTS AGREEMENT between SHIN NIPPON BIOMEDICAL LABORATORIES, LTD., and AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, as the Rights Agent Dated as of June 6, 2023 TABLE OF CONTENTS Page SECTION 1 DEFINITIONS 1 1.1 Definitions 1 SECTION 2 CONTINGENT VALUE RIGHTS 4 2.1 Authority; Issuance of CVRs; Appointment of Rights Agent 4 2.2 Nontra
June 8, 2023	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) SATSUMA PHARMACEUTICALS, INC. (Name of Subject Co SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) SATSUMA PHARMACEUTICALS, INC. (Name of Subject Company) SNBL23 Merger Sub, Inc. (Name of Filing Persons—Offeror) A Wholly Owned Subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (Name
June 8, 2023	EX-3.1	FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION SATSUMA PHARMACEUTICALS, INC ARTICLE I Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SATSUMA PHARMACEUTICALS, INC ARTICLE I The name of the corporation is SATSUMA PHARMACEUTICALS, INC. (the “Company”). ARTICLE II The address of the Company’s registered office in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle, Delaware 19801. The name of the registered agent at such
June 8, 2023	EX-3.2	BYLAWS OF SATSUMA PHARMACEUTICALS, INC. Adopted June 8, 2023 EX-3.2 Exhibit 3.2 Execution Version BYLAWS OF SATSUMA PHARMACEUTICALS, INC. Adopted June 8, 2023 TABLE OF CONTENTS ARTICLE I — MEETINGS OF STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meeting 1 1.4 Notice of Stockholders’ Meetings 2 1.5 Quorum 2 1.6 Adjourned Meeting; Notice 2 1.7 Conduct of Business 2 1.8 Voting 3 1.9 Stockholder Action by Written Consent Without a Mee
June 8, 2023	POS AM	As filed with the Securities and Exchange Commission on June 8, 2023 POS AM As filed with the Securities and Exchange Commission on June 8, 2023 Registration No.
June 8, 2023	POS AM	As filed with the Securities and Exchange Commission on June 8, 2023 POS AM 1 d497652dposam.htm POS AM As filed with the Securities and Exchange Commission on June 8, 2023 Registration No. 333-249645 Registration No. 333-255201 Registration No. 333-268035 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-249645 REGISTRATION STATEMENT NO. 333-255201 REGISTRATION STATEMENT
June 8, 2023	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 4) SATSUMA PHARMACEUTICALS, INC. SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 4) SATSUMA PHARMACEUTICALS, INC. (Name of Subject Company) SATSUMA PHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title o
June 8, 2023	S-8 POS	As filed with the Securities and Exchange Commission on June 8, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 8, 2023 Registration No.
June 8, 2023	S-8 POS	As filed with the Securities and Exchange Commission on June 8, 2023 S-8 POS As filed with the Securities and Exchange Commission on June 8, 2023 Registration No.
June 8, 2023	POS AM	As filed with the Securities and Exchange Commission on June 8, 2023 As filed with the Securities and Exchange Commission on June 8, 2023 Registration No.
June 8, 2023	SC 13D/A	STSA / Satsuma Pharmaceuticals Inc / Shin Nippon Biomedical Laboratories, Ltd. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 2)* Under the Securities Exchange Act of 1934 SATSUMA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 80405P107 (CUSIP Number) Shinji Nitanda Shin Nippon Biomedical Laboratories, Ltd. 2438 Miyanoura-cho, Kagoshima-shi, Kagosh
June 8, 2023	EX-99.(A)(5)(IV)	Results of Tender Offer for All Outstanding Shares of Satsuma Pharmaceuticals, Inc. Not Owned by SNBL and Change in Subsidiaries Upon Completion of Transaction EX-99.(a)(5)(iv) Exhibit (a)(5)(iv) Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. June 9, 2023 Company Name Shin Nippon Biomedical Laboratories, Ltd. Representative Representative Chairman, President & CEO Ryoichi Nagata Listing T
June 8, 2023	S-8 POS	As filed with the Securities and Exchange Commission on June 8, 2023 S-8 POS 1 d515898ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on June 8, 2023 Registration No. 333-233808 Registration No. 333-237058 Registration No. 333-254737 Registration No. 333-263611 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-233808 POST-EFFECTIVE AMENDMENT NO. 1
June 8, 2023	S-8 POS	As filed with the Securities and Exchange Commission on June 8, 2023 As filed with the Securities and Exchange Commission on June 8, 2023 Registration No.
June 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 SATSUMA PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Commiss
June 8, 2023	SC 13E3/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Rule 13e-100) Rule 13e-3 Transaction Statement Under Section 13(e) of the Securities Exchange Act of 1934 (Amendment No. 4) Satsuma Pharmaceuticals, Inc. (Name of the Issuer) S SC 13E3/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Rule 13e-100) Rule 13e-3 Transaction Statement Under Section 13(e) of the Securities Exchange Act of 1934 (Amendment No. 4) Satsuma Pharmaceuticals, Inc. (Name of the Issuer) Satsuma Pharmaceuticals, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 804
May 31, 2023	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) SATSUMA PHARMACEUTICALS, INC. SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) SATSUMA PHARMACEUTICALS, INC. (Name of Subject Company) SATSUMA PHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title o
May 31, 2023	SC 13E3/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Rule 13e-100) Rule 13e-3 Transaction Statement Under Section 13(e) of the Securities Exchange Act of 1934 (Amendment No. 3) Satsuma Pharmaceuticals, Inc. (Name of the Issuer) S SC 13E3/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Rule 13e-100) Rule 13e-3 Transaction Statement Under Section 13(e) of the Securities Exchange Act of 1934 (Amendment No. 3) Satsuma Pharmaceuticals, Inc. (Name of the Issuer) Satsuma Pharmaceuticals, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 804
May 26, 2023	EX-FILING FEES	Calculation of Filing Fee Table Table 1 - Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to Be Paid $27,628,553.19(1) 0.00011020 $3,044.67(2) Fees Previously Paid $27,628,553.19 $3,044.67 Total Transaction Valuation $2 EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Table 1 - Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to Be Paid $27,628,553.
May 26, 2023	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) SATSUMA PHARMACEUTICALS, INC. (Name of Subject Co SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) SATSUMA PHARMACEUTICALS, INC. (Name of Subject Company) SNBL23 Merger Sub, Inc. (Name of Filing Persons—Offeror) A Wholly Owned Subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (Name
May 25, 2023	SC 13E3/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Rule 13e-100) Rule 13e-3 Transaction Statement Under Section 13(e) of the Securities Exchange Act of 1934 (Amendment No. 2) Satsuma Pharmaceuticals, Inc. (Name of the Issuer) S SC 13E3/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Rule 13e-100) Rule 13e-3 Transaction Statement Under Section 13(e) of the Securities Exchange Act of 1934 (Amendment No. 2) Satsuma Pharmaceuticals, Inc. (Name of the Issuer) Satsuma Pharmaceuticals, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 804
May 25, 2023	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) SATSUMA PHARMACEUTICALS, INC. SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) SATSUMA PHARMACEUTICALS, INC. (Name of Subject Company) SATSUMA PHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title o
May 24, 2023	CORRESP	* * * * CORRESP May 24, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
May 18, 2023	EX-99.1	Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine EX-99.1 Exhibit 99.1 Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine • January 2024 PDUFA date expected • If approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial (the SUMMIT trial) against modern outcome measure
May 18, 2023	SC 13E3/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Rule 13e-100) Rule 13e-3 Transaction Statement Under Section 13(e) of the Securities Exchange Act of 1934 (Amendment No. 1) Satsuma Pharmaceuticals, Inc. (Name of the Issuer) S SC 13E3/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Rule 13e-100) Rule 13e-3 Transaction Statement Under Section 13(e) of the Securities Exchange Act of 1934 (Amendment No. 1) Satsuma Pharmaceuticals, Inc. (Name of the Issuer) Satsuma Pharmaceuticals, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 804
May 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 SATSUMA PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Commiss
May 18, 2023	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) SATSUMA PHARMACEUTICALS, INC. SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) SATSUMA PHARMACEUTICALS, INC. (Name of Subject Company) SATSUMA PHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title o
May 11, 2023	EX-10.2	Separation Agreement, dated March 31, 2023, by and between Detlef Albrecht and Satsuma Pharmaceuticals, Inc. Exhibit 10.2 This document supersedes any previous version shared with you SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS + This Separation Agreement and General Release of Claims (“Separation Agreement”) is entered as of 3/31/2023 (“Effective Date”) into by Detlef Albrecht (“Employee”), and Satsuma, Inc., together with subsidiaries, affiliates (including TriNet Group, Inc.), predecessors and
May 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39041 Satsuma Pharmaceuticals, Inc.
May 5, 2023	EX-99.(A)(1)(VI)	Summary Advertisement as published in the New York Times on May 5, 2023 (incorporated by reference to Exhibit (a)(1)(vi) to the Schedule TO). EX-99.(a)(1)(vi) Exhibit (a)(1)(vi) SUMMARY ADVERTISEMENT This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely by the Offer to Purchase, dated May 5, 2023 and the related Letter of Transmittal and any amendments or supplements thereto. Purchaser (as defined below) is not aware of any state wh
May 5, 2023	EX-99.(A)(1)(V)	Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies, and Other Nominees (incorporated by reference to Exhibit (a)(1)(v) to the Schedule TO). EX-99.(a)(1)(v) Exhibit (a)(1)(v) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Satsuma Pharmaceuticals, Inc. at $0.91 per share, net in cash, plus one non-transferable contractual contingent value right per share, which represents the right to receive one or more payments in cash, contingent upon the achievement of certain net proceed thresholds, pursuant to the Offer to Pu
May 5, 2023	EX-99.(A)(9)	Letter to Stockholders of the Company, dated May 5, 2023, from John Kollins, President and Chief Executive Officer of the Company. EX-99.(A)(9) Exhibit (a)(9) Satsuma Pharmaceuticals, Inc. 4819 Emperor Boulevard, Suite 340 Durham, NC 27703 May 5, 2023 Dear Stockholder: We are pleased to inform you that, on April 16, 2023, Satsuma Pharmaceuticals, Inc. (“Satsuma”) entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with Shin Nippon Biomedical Laboratories, Ltd. (“Parent”) and SNBL23 Merger Sub, Inc.
May 5, 2023	EX-99.(F)	Section 262 of the Delaware General Corporation Law. EX-99.(f) Exhibit F § 262. Appraisal rights (a) Any stockholder of a corporation of this State who holds shares of stock on the date of the making of a demand pursuant to subsection (d) of this section with respect to such shares, who continuously holds such shares through the effective date of the merger, consolidation, or conversion, who has otherwise complied with subsection (d) of this section
May 5, 2023	EX-FILING FEES	Filing Fee Table. EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 13E-3 (Form Type) Satsuma Pharmaceuticals, Inc.
May 5, 2023	EX-99.(A)(1)(IV)	Letter to Brokers, Dealers, Commercial Banks, Trust Companies, and Other Nominees (incorporated by reference to Exhibit (a)(1)(iv) to the Schedule TO). EX-99.(a)(1)(iv) Exhibit (a)(1)(iv) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Satsuma Pharmaceuticals, Inc. at $0.91 per share, net in cash, plus one non-transferable contractual contingent value right per share, which represents the right to receive one or more payments in cash, contingent upon the achievement of certain net proceed thresholds, pursuant to the Offer to
May 5, 2023	EX-99.(A)(1)(III)	Notice of Guaranteed Delivery (incorporated by reference to Exhibit (a)(1)(iii) to the Schedule TO). EX-99.(a)(1)(iii) Exhibit (a)(1)(iii) NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock of Satsuma Pharmaceuticals, Inc. at $0.91 per share, net in cash, plus one non-transferable contractual contingent value right per share, which represents the right to receive one or more payments in cash, contingent upon the achievement of certain net proceed thresholds, pursuant to the Offer to P
May 5, 2023	EX-99.(A)(1)(I)	Offer to Purchase, dated May 5, 2023 (incorporated by reference to Exhibit (a)(1)(i) to the Parent and Purchaser’s Tender Offer Statement on Schedule TO filed with the SEC on May 5, 2023 (the “Schedule TO”)). EX-99.(a)(1)(i) Table of Contents Exhibit (a)(1)(i) OFFER TO PURCHASE FOR CASH All Outstanding Shares of Common Stock of SATSUMA PHARMACEUTICALS, INC. a Delaware Corporation at $0.91 per Share, net in cash, plus one non-transferable contractual contingent value right for each share, which represents the right to receive one or more payments in cash, contingent upon the achievement of certain net p
May 5, 2023	EX-FILING FEES	Calculation of Filing Fee Table Table 1 - Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to Be Paid $27,628,553.19 (1) 0.00011020 $3,044.67 (2) Fees Previously Paid — — Total Transaction Valuation $27,628,553.19 Total EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Table 1 - Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to Be Paid $27,628,553.
May 5, 2023	SC 14D9	Opinion of Houlihan Lokey Capital, Inc., dated April 16, 2023 (incorporated by reference to Annex A attached to the Company’s Solicitation/Recommendation Statement on Schedule 14D-9 filed with the SEC on May 5, 2023). SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 5, 2023	SC TO-T	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SATSUMA PHARMACEUTICALS, INC. (Name of Subject Company) SNBL23 Merger SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SATSUMA PHARMACEUTICALS, INC. (Name of Subject Company) SNBL23 Merger Sub, Inc. (Offeror) A Wholly Owned Subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (Parent of Offeror) (Names of Filing Persons—Offer
May 5, 2023	SC 13E3	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Rule 13e-100) Rule 13e-3 Transaction Statement Under Section 13(e) of the Securities Exchange Act of 1934 (Amendment No. __) Satsuma Pharmaceuticals, Inc. (Name of the Issuer) SC 13E3 1 d240954dsc13e3.htm SC 13E3 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Rule 13e-100) Rule 13e-3 Transaction Statement Under Section 13(e) of the Securities Exchange Act of 1934 (Amendment No. ) Satsuma Pharmaceuticals, Inc. (Name of the Issuer) Satsuma Pharmaceuticals, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title o
May 5, 2023	EX-99.(C)(2)	Presentation of J. Houlihan Lokey, Inc. to the Independent Directors of the Board of Directors of the Company, dated April 16, 2023. EX-99.(c)(2) EXHIBIT C2 Project Naranja DISCUSSION MATERIALS FOR THE BOARD OF DIRECTORS OF SATSUMA PHARMACEUTICALS, INC. APRIL 16, 2023 \| CONFIDENTIAL Table of Contents Page 1. Executive Summary 3 2. Financial Analyses 8 3. Selected Public Market Observations 14 4. Disclaimer 23 2 CONFIDENTIAL Page 1. Executive Summary 3 2. Financial Analyses 8 3. Selected Public Market Observations 14 4. Disclaim
May 5, 2023	EX-99.(A)(1)(II)	Letter of Transmittal (including Guidelines for Certification of Taxpayer Identification Number on IRS Form W-9) (incorporated by reference to Exhibit (a)(1)(ii) to the Schedule TO). EX-99.(a)(1)(ii) Exhibit (a)(1)(ii) Letter of Transmittal to tender Shares of Common Stock of SATSUMA PHARMACEUTICALS, INC. Pursuant to the Offer to Purchase dated May 5, 2023 by SNBL23 MERGER SUB, INC., a wholly-owned subsidiary of SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. The undersigned represents that I (we) have full authority to surrender without restriction the shares and, if applicable, th
May 5, 2023	EX-99.(A)(5)(III)	Press Release issued by Parent on May 5, 2023 (incorporated by reference to Exhibit (a)(5)(iii) to the Schedule TO). EX-99.(a)(5)(iii) Exhibit (a)(5)(iii) Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. May 8, 2023 Company Name Shin Nippon Biomedical Laboratories, Ltd. Representative Representative Chairman, President & CEO Ryoichi Nagata Listing
May 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 SATSUMA PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Commissi
May 2, 2023	SC 13D/A	STSA / Satsuma Pharmaceuticals Inc / Growth Equity Opportunities 17, LLC - GROWTH EQUITY OPPORTUNITIES 17, LLC / SATSUMA PHARMACEUTICALS -- 13D/A(#2E) Activist Investment Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 80405P107 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410
April 28, 2023	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No.
April 18, 2023	SC 13D/A	STSA / Satsuma Pharmaceuticals Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response… 10.4 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 80405P107 (CUSIP Num
April 17, 2023	SC 13D/A	STSA / Satsuma Pharmaceuticals Inc / Shin Nippon Biomedical Laboratories, Ltd. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 1)* Under the Securities Exchange Act of 1934 SATSUMA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 80405P107 (CUSIP Number) Shinji Nitanda Shin Nippon Biomedical Laboratories, Ltd. 2438 Miyanoura-cho, Kagoshima-shi, Kagosh
April 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2023 SATSUMA PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2023 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Commi
April 17, 2023	SC14D9C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Satsuma Pharmaceuticals, Inc. (Name of Subject C SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Satsuma Pharmaceuticals, Inc. (Name of Subject Company) Satsuma Pharmaceuticals, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securiti
April 17, 2023	EX-99.1	JOINT FILING AGREEMENT EX-99.1 Exhibit 1 JOINT FILING AGREEMENT JOINT FILING AGREEMENT dated as of April 16, 2023, by and among Shin Nippon Biomedical Laboratories, Ltd., SNBL U.S.A., Ltd., SNBL23 Merger Sub, Inc. and Ken Takanashi (collectively, the “Joint Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D with respect to the shares
April 17, 2023	EX-99.1	SNBL to Acquire Satsuma Pharmaceuticals Transaction delivers immediate value and liquidity to Satsuma stockholders SNBL to acquire all outstanding shares of Satsuma for upfront cash consideration of $0.91 per share Satsuma stockholders to also receiv EX-99.1 Exhibit 99.1 Satsuma Pharmaceuticals, Inc. SNBL to Acquire Satsuma Pharmaceuticals Transaction delivers immediate value and liquidity to Satsuma stockholders SNBL to acquire all outstanding shares of Satsuma for upfront cash consideration of $0.91 per share Satsuma stockholders to also receive non-tradeable CVR of up to $5.77 per share With the goal of maximizing value for stockholders, Sa
April 17, 2023	EX-2.1	Agreement and Plan of Merger, dated as of April 16, 2023, among Parent, Purchaser and the Company (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 17, 2023). EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among SHIN NIPPON BIOMEDICAL LABORATORIES, LTD., SATSUMA PHARMACEUTICALS, INC. and SNBL23 MERGER SUB, INC. Dated as of April 16, 2023 TABLE OF CONTENTS Page ARTICLE I THE OFFER 2 1.1 The Offer 2 1.2 Company Actions 6 1.3 Schedule 13E-3 7 ARTICLE II THE MERGER; CLOSING; SURVIVING COMPANY 8 2.1 The Merger 8 2.2 Closing 8 2.3 Effective Time 8 2.4 The Ce
April 17, 2023	EX-99.1	Press release issued by SHIN NIPPON BIOMEDICAL LABORATORIES, LTD., on April 17, 2023. EX-99.1 Exhibit 99.1 PRESS RELEASE April 17, 2023 SNBL Enters into Definitive Agreement to Acquire Satsuma Pharmaceuticals, Inc. TOKYO and KAGOSHIMA, Japan, April 17, 2023 – Shin Nippon Biomedical Laboratories, Ltd. (TSE Prime: 2395, Chairman and President: Ryoichi Nagata, M.D., Ph.D., “SNBL” or “Company”) and a licensee of SNBL’s nasal delivery platform technology, Satsuma Pharmaceuticals, Inc. (
April 17, 2023	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SATSUMA PHARMACEUTICALS, INC. (Name of Subject Company) SHIN NIPPON B SC TO-C 1 d496988dsctoc.htm SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SATSUMA PHARMACEUTICALS, INC. (Name of Subject Company) SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (Names of Filing Persons – Offeror) Common Stock, Par Value $0.0001 Per Share (Title
April 17, 2023	EX-10.1	Form of Contingent Value Rights Agreement to be entered into between Shin Nippon Biomedical Laboratories, Ltd. and American Stock Transfer & Trust Company, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 17, 2023). EX-10.1 Exhibit 10.1 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT between SHIN NIPPON BIOMEDICAL LABORATORIES, LTD., and AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, as the Rights Agent Dated as of [ ], 2023 TABLE OF CONTENTS Page SECTION 1 DEFINITIONS 1 1.1 Definitions 1 SECTION 2 CONTINGENT VALUE RIGHTS 4 2.1 Authority; Issuance of CVRs; Appointment of Rights Agent. 4 2.2 Nontransferable 5 2.3 No
April 17, 2023	EX-2.2	Tender and Support Agreement, dated as of April 16, 2023, by among Parent., Purchaser and certain stockholders and directors of the Company (incorporated by reference to Exhibit 2.2 to the Company’s Current Report on Form 8-K filed with the SEC on April 17, 2023). EX-2.2 Exhibit 2.2 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”) is entered into as of April 16, 2023, by and among Shin Nippon Biomedical Laboratories, Ltd., a Japanese corporation (“Parent”), SNBL23 Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Purchaser”), and each of the undersigned stockholders of Satsuma Pharmaceuticals,
April 17, 2023	EX-99.2	Notice to Tokyo Stock Exchange that “SNBL Enters into Definitive Agreement to Acquire Satsuma Pharmaceuticals, Inc.” EX-99.2 Exhibit 99.2 Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. April 17, 2023 Company Name Shin Nippon Biomedical Laboratories, Ltd. Representative Representative Chairman, President & CEO Ryoichi Nagata Listing TSE PRIME : ti
March 28, 2023	10-K	Power of Attorney. Reference is made to the signature page to the Registration Statement. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39041 Satsuma Pharmaceuticals, Inc.
March 28, 2023	EX-4	Description of Capital Stock EX-4 2 stsa-ex46.htm EX-4.6 Exhibit 4.6 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes our capital stock and the material provisions of our amended and restated certificate of incorporation and our amended and restated bylaws, the amended and restated investors’ rights agreement to which we and certain
March 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 SATSUMA PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Commi
March 28, 2023	EX-99.1	Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights - Announced topline results from STS101 SUMMIT Phase 3 efficacy trial that the company believes demonstrate STS101 provides differentia EX-99.1 Exhibit 99.1 Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights - Announced topline results from STS101 SUMMIT Phase 3 efficacy trial that the company believes demonstrate STS101 provides differentiated, robust and sustained anti-migraine effects - - Submitted STS101 New Drug Application (NDA) to U.S. Food and Drug Administrat
February 16, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Co
February 16, 2023	EX-99.1	Disclaimer Important Notice This Presentation contains forward-looking statements concerning the business, operations and financial performance and condition of Satsuma Pharmaceuticals, Inc. (the “Company”), as well as the Company’s plans, objectives EX-99.1 2 d466199dex991.htm EX-99.1 SVB Securities Global Biopharma Conference STS101 program and corporate overview NASDAQ: STSA \| February 16, 2023 Exhibit 99.1 Disclaimer Important Notice This Presentation contains forward-looking statements concerning the business, operations and financial performance and condition of Satsuma Pharmaceuticals, Inc. (the “Company”), as well as the Company’s plan
February 14, 2023	SC 13G/A	STSA / Sterling Financial Corp / SAMLYN CAPITAL, LLC Passive Investment SC 13G/A 1 d991377913ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 80405P107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropria
February 10, 2023	SC 13G/A	STSA / Sterling Financial Corp / TPG GP A, LLC - AMENDMENT TO FORM SC 13G Passive Investment SC 13G/A 1 satsuma-sc13ga020923.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2)* Under the Securities Exchange Act of 1934 Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Titles of Class of Securities) 80405P107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires
February 8, 2023	SC 13G/A	STSA / Sterling Financial Corp / BML Investment Partners, L.P. - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 80405P107 (CUSIP Number) Calendar Year 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate
January 27, 2023	SC 13D/A	STSA / Sterling Financial Corp / Growth Equity Opportunities 17, LLC - GROWTH EQUITY OPPORTUNITIES 17, LLC / SATSUMA PHARMACEUTICALS -- 13D/A(#1) Activist Investment SC 13D/A 1 geo17-satsuma18692.htm GROWTH EQUITY OPPORTUNITIES 17, LLC / SATSUMA PHARMACEUTICALS - 13D/A(#1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 80405P107 (CUSIP Number) Louis S. Ci
December 20, 2022	EX-99.2	pharmaceuticals STS101 program and corporate overview NASDAQ: STSA \| December 20, 2022 Exhibit 99.2 pharmaceuticals STS101 program and corporate overview NASDAQ: STSA \| December 20, 2022 Satsuma Pharmaceuticals corporate summary and STS101 program overview 2 Satsuma Pharmaceuticals (Nasdaq: STSA) Focus ? Developing STS101 (DHE nasal powder) for the acute treatment of migraine o Differentiated, NDA-stage asset with low regulatory risk and significant commercial potential Financial ?
December 20, 2022	EX-99.1	Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update EX-99.1 2 d420710dex991.htm EX-99.1 Exhibit 99.1 PRESS RELEASE Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update • Further analysis of results from recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine shows differentiating robust and sustained antimigraine effects on clinically important secondary endpoints • Qualitative and
December 20, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2022 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Co
November 30, 2022	EX-99.1	Disclaimer Important Notice This Presentation contains forward-looking statements concerning the business, operations and financial performance and condition of Satsuma Pharmaceuticals, Inc. (the “Company”), as well as the Company’s plans, objectives Exhibit 99.1 pharmaceuticals Satsuma Pharmaceuticals and STS101 Update 5th Annual Evercore ISI HealthCONx Conference November 30, 2022 Disclaimer Important Notice This Presentation contains forward-looking statements concerning the business, operations and financial performance and condition of Satsuma Pharmaceuticals, Inc. (the ?Company?), as well as the Company?s plans, objectives and expectatio
November 30, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Co
November 16, 2022	SC 13G/A	STSA / Sterling Financial Corp / COMMODORE CAPITAL LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
November 16, 2022	SC 13G	STSA / Sterling Financial Corp / BML Investment Partners, L.P. - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 80405P107 (CUSIP Number) November 14, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropria
November 14, 2022	EX-99.2	Disclaimer Important Notice This Presentation contains forward-looking statements concerning the business, operations and financial performance and condition of Satsuma Pharmaceuticals, Inc. (the “Company”), as well as the Company’s plans, objectives STS101 for the acute treatment of migraine SUMMIT Phase 3 efficacy trial topline results November 14, 2022 conference call Exhibit 99.
November 14, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Co
November 14, 2022	EX-99.1	Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase 3 Trial of STS101 for the Acute Treatment of Migraine EX-99.1 2 d405306dex991.htm EX-99.1 Exhibit 99.1 PRESS RELEASE Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase 3 Trial of STS101 for the Acute Treatment of Migraine • STS101 was not statistically superior to placebo at two hours post-administration on the co-primary endpoints of freedom from pain and most bothersome symptom • STS101 showed superiority (p<0.001) differences vers
November 3, 2022	EX-99.1	Satsuma Pharmaceuticals Reports Third Quarter 2022 Financial Results and Recent Business Highlights - On track to report topline results from STS101 SUMMIT Phase 3 efficacy trial in November 2022; NDA submission planned in Q1 2023 - - $64.4 million i Exhibit 99.1 Satsuma Pharmaceuticals, Inc. PRESS RELEASE Satsuma Pharmaceuticals Reports Third Quarter 2022 Financial Results and Recent Business Highlights - On track to report topline results from STS101 SUMMIT Phase 3 efficacy trial in November 2022; NDA submission planned in Q1 2023 - - $64.4 million in cash, cash equivalents and marketable securities as of September 30, 2022, provides runway
November 3, 2022	CORRESP	Satsuma Pharmaceuticals, Inc. 400 Oyster Point Boulevard, Suite 221 South San Francisco, CA 94080 Satsuma Pharmaceuticals, Inc. 400 Oyster Point Boulevard, Suite 221 South San Francisco, CA 94080 November 3, 2022 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Alan Campbell Re: Satsuma Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed October 28,
November 3, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Com
November 3, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Com
November 3, 2022	424B5	Up to $100,000,000 Common Stock 424B5 1 d418029d424b5.htm 424B5 Table of Contents As Filed Pursuant to 424(b)(5) Registration No. 333-249645 PROSPECTUS SUPPLEMENT (To Prospectus Dated November 12, 2020) Up to $100,000,000 Common Stock We have entered into an At-the-Market Sales Agreement (the Sales Agreement), with Virtu Americas LLC (Virtu), relating to the sale of shares of our common stock, par value $0.0001 per share, offere
November 3, 2022	EX-1.1	At-The-Market Sales Agreement by and between the Registrant and Virtu Americas LLC, dated November 3, 2022. EX-1.1 2 d417978dex11.htm EX-1.1 Exhibit 1.1 Execution Version SATSUMA PHARMACEUTICALS, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT November 3, 2022 Virtu Americas LLC 1633 Broadway New York, NY 10019 Ladies and Gentlemen: Satsuma Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Virtu Americas LLC (the “Agen
November 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39041 Satsuma Pharmaceuticals, Inc.
October 28, 2022	S-3	As filed with the Securities and Exchange Commission on October 27, 2022 Table of Contents As filed with the Securities and Exchange Commission on October 27, 2022 Registration No.
October 28, 2022	EX-FILING FEES	Filing fee table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Satsuma Pharmaceuticals, Inc.
October 28, 2022	8-K	Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Com
September 20, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2022 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (C
September 20, 2022	EX-99.1	Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial EX-99.1 2 d399674dex991.htm EX-99.1 Exhibit 99.1 Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial • STS101 demonstrated a favorable safety and tolerability profile, consistent with clinical experience to date • Over 8,000 migraine attacks treated with more than 10,000 doses of STS101; of which, over 5,500 migraine attacks
August 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Commi
August 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39041 Satsuma Pharmaceuticals, Inc.
August 9, 2022	EX-99.1	Satsuma Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Progress in STS101 Development Program - Completed enrollment in the SUMMIT pivotal Phase 3 efficacy trial of STS101, randomizing more than 1,400 subjects - - On track t EX-99.1 2 d386008dex991.htm EX-99.1 Exhibit 99.1 Satsuma Pharmaceuticals, Inc. PRESS RELEASE Satsuma Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Progress in STS101 Development Program - Completed enrollment in the SUMMIT pivotal Phase 3 efficacy trial of STS101, randomizing more than 1,400 subjects - - On track to announce SUMMIT trial topline results in Q4 2022 - - Co
June 7, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2022 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Commiss
May 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39041 Satsuma Pharmaceuticals, Inc.
May 10, 2022	EX-99.1	Satsuma Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights - STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing and on track to read out topline results in Q4 2022 – - New Drug Application (NDA) submissio Exhibit 99.1 PRESS RELEASE Satsuma Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights - STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing and on track to read out topline results in Q4 2022 ? - New Drug Application (NDA) submission anticipated in Q1 2023 - - $80.6 million in cash, cash equivalents and marketable securities as of March 31, 2022, provid
May 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Commiss
April 20, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A 1 d294473ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule
April 19, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi
March 16, 2022	EX-FILING FEES	Fee Filing Table Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Satsuma Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock
March 16, 2022	S-8	As filed with the Securities and Exchange Commission on March 16, 2022 S-8 1 d331239ds8.htm REGISTRATION STATEMENT ON FORM S-8 As filed with the Securities and Exchange Commission on March 16, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Satsuma Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 2834 81-3039831 (Sta
March 15, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39041 Satsuma Pharmaceuticals, Inc.
March 15, 2022	EX-4.6	Description of Capital Stock Exhibit 4.6 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes our capital stock and the material provisions of our amended and restated certificate of incorporation and our amended and restated bylaws, the amended and restated investors? rights agreement to which we and certain of our stockholders are par
March 15, 2022	EX-99.1	Satsuma Pharmaceuticals Reports 2021 Full Year and Fourth Quarter Financial Results and Business Highlights - STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing; key trial on track to read out topline results in Q4 2022 - - $95.8 million in cash Exhibit 99.1 PRESS RELEASE Satsuma Pharmaceuticals Reports 2021 Full Year and Fourth Quarter Financial Results and Business Highlights - STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing; key trial on track to read out topline results in Q4 2022 - - $95.8 million in cash, cash equivalents and marketable securities as of December 31, 2021, provides runway into second half of 2023 - March 15,
March 15, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Commi
February 25, 2022	SC 13G/A	STSA / Sterling Financial Corp / SAMLYN CAPITAL, LLC Passive Investment SC 13G/A 1 d937550813g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 80405P107 (CUSIP Number) February 15, 2022 (Date of Event Which Requires Filing of this Statement) Check th
February 14, 2022	SC 13G/A	STSA / Sterling Financial Corp / COMMODORE CAPITAL LP - SC 13G/A Passive Investment SC 13G/A 1 satsumapharm13gam2dec312021.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 80405P107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of t
February 14, 2022	SC 13G	STSA / Sterling Financial Corp / SAMLYN CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 11, 2022	SC 13G/A	STSA / Sterling Financial Corp / TPG GP A, LLC - AMENDMENT TO FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1)* Under the Securities Exchange Act of 1934 Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Titles of Class of Securities) 80405P107 (CUSIP Number) January 12, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
November 9, 2021	EX-99.1	Satsuma Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update - STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing, with topline results expected second half of 2022 - - Appointed Mutya Harsch to the Board of EX-99.1 Exhibit 99.1 PRESS RELEASE Satsuma Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update - STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing, with topline results expected second half of 2022 - - Appointed Mutya Harsch to the Board of Directors - - $110 million in cash as of September 30, 2021 provides runway into second half of 2023 - South San F
November 9, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39041 Satsuma Pharmaceuticals, Inc.
November 9, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Com
October 19, 2021	SC 13G/A	STSA / Sterling Financial Corp / COMMODORE CAPITAL LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
October 12, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2021 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Com
August 10, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39041 Satsuma Pharmaceuticals, Inc.
August 10, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d187464d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdictio
August 10, 2021	EX-99.1	Satsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Business Highlights - Initiated STS101 SUMMIT Phase 3 efficacy trial; topline results expected second half 2022- - $121.2 million in cash as of June 30, 2021, provides r Exhibit 99.1 PRESS RELEASE Satsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Business Highlights - Initiated STS101 SUMMIT Phase 3 efficacy trial; topline results expected second half 2022- - $121.2 million in cash as of June 30, 2021, provides runway into second half of 2023- South San Francisco, CA, August 10, 2021 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a
June 16, 2021	EX-99.1	Satsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety Results From Phase 1 Trial of STS101 at Multiple Dose Strengths - All three dose strengths of STS101, administered with improved 2nd-generation nasal delivery device EX-99.1 2 d185844dex991.htm EX-99.1 Exhibit 99.1 PRESS RELEASE Satsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety Results From Phase 1 Trial of STS101 at Multiple Dose Strengths - All three dose strengths of STS101, administered with improved 2nd-generation nasal delivery device were well-tolerated and achieved target pharmacokinetic profile - - Initiating SUMMIT P
June 16, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Commis
June 2, 2021	8-K	Submission of Matters to a Vote of Security Holders 8-K 1 d439812d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdict
May 11, 2021	EX-99.1	Satsuma Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Business Highlights -New STS101 Phase 3 efficacy trial (the SUMMIT trial) expected to begin mid-2021 with topline results expected second half of 2022- -Results expected Exhibit 99.1 PRESS RELEASE Satsuma Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Business Highlights -New STS101 Phase 3 efficacy trial (the SUMMIT trial) expected to begin mid-2021 with topline results expected second half of 2022- -Results expected in Q2 from ongoing Phase 1 trial to inform dose selection for Phase 3- -$133 million in cash, cash equivalents and marketab
May 11, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39041 Satsuma Pharmaceuticals, Inc.
May 11, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Commiss
May 6, 2021	424B3	SATSUMA PHARMACEUTICALS, INC. 14,084,507 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-255201 PROSPECTUS SUPPLEMENT SATSUMA PHARMACEUTICALS, INC. 14,084,507 Shares of Common Stock The selling securityholders may offer and sell up to 14,084,507 shares of our common stock, par value $0.0001 per share (the ?Common Stock?), from time to time in one or more offerings. This prospectus provides you with a general descr
April 28, 2021	CORRESP	Satsuma Pharmaceuticals, Inc. 400 Oyster Point Boulevard., Suite 221 South San Francisco, CA 94080 Satsuma Pharmaceuticals, Inc. 400 Oyster Point Boulevard., Suite 221 South San Francisco, CA 94080 April 28, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Irene Paik Re: Satsuma Pharmaceuticals, Inc. Registration Statement on Form S-3 (Registration No. 333-255201) Ladies and Gentlemen: In accordance with Rule 46
April 19, 2021	DEF 14A	- DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi
April 19, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
April 13, 2021	S-3	- S-3 Table of Contents AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON APRIL 13, 2021 Registration No.
March 31, 2021	EX-99.1	JOINT FILING AGREEMENT EX-99.1 Exhibit 1 JOINT FILING AGREEMENT JOINT FILING AGREEMENT dated as of March 29, 2021, by and among Shin Nippon Biomedical Laboratories, Ltd., SNBL U.S.A., Ltd. and Ken Takanashi (collectively, the “Joint Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D with respect to the shares of Common Stock of Satsu
March 31, 2021	SC 13D	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Information To Be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) SATSUMA PHARMACEUTICALS, INC. (Name SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Information To Be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) SATSUMA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 80405P107 (CUSIP Number) Ken Takanashi St. Luke’s To
March 26, 2021	S-8	- REGISTRATION STATEMENT ON FORM S-8 As filed with the Securities and Exchange Commission on March 25, 2021 Registration No.
March 25, 2021	10-K	Annual Report - 10-K - 2020 10-K 1 stsa-10k20201231.htm 10-K - 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission
March 25, 2021	EX-4.6	Description of Common Stock. EX-4.6 2 stsa-ex4610.htm EX-4.6 Exhibit 4.6 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes our capital stock and the material provisions of our amended and restated certificate of incorporation and our amended and restated bylaws, the amended and restated investors’ rights agreement to which we and cer
March 25, 2021	EX-99.1	Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights Announced updated STS101 development plan featuring a new Phase 3 efficacy trial scheduled to begin enrollment mid-2021 with topline re Exhibit 99.1 Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights Announced updated STS101 development plan featuring a new Phase 3 efficacy trial scheduled to begin enrollment mid-2021 with topline results expected in second half of 2022 Closed $80 million private placement of common stock financing with new and existing investors Cash
March 25, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2021 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Commi
March 15, 2021	EX-1	JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.
March 15, 2021	SC 13D	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. __ )* Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Secu Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 80405P107 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410)
March 15, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Satsuma Pharmaceuticals, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
March 2, 2021	SC 13D/A	UNITED STATES UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response… 10.4 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 80405P107 (CUSIP Num
March 1, 2021	EX-10.2	Registration Rights Agreement, effective March 3, 2021 (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on March 1, 2021). EX-10.2 3 d136544dex102.htm EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of March 3, 2021 by and among Satsuma Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of February 2
March 1, 2021	EX-99.1	Satsuma Pharmaceuticals Announces Updated STS101 Development Plan -New STS101 Phase 3 efficacy trial planned to begin mid-2021 with topline results expected second half of 2022- -Proceeds from $80 million private placement and existing cash expected Exhibit 99.1 PRESS RELEASE Satsuma Pharmaceuticals Announces Updated STS101 Development Plan -New STS101 Phase 3 efficacy trial planned to begin mid-2021 with topline results expected second half of 2022- -Proceeds from $80 million private placement and existing cash expected to fund operations into second half of 2023- -Conference call this morning at 8:00 AM ET; dial in details are listed below-
March 1, 2021	EX-99.2	Important Notice This Presentation contains forward-looking statements concerning the business, operations and financial performance and condition of Satsuma Pharmaceuticals, Inc. (the “Company”), as well as the Company’s plans, objectives and expect EX-99.2 5 d136544dex992.htm EX-99.2 Corporate and STS101 (DHE nasal powder for migraine) program update Conference call March 1, 2021 NASDAQ: STSA Exhibit 99.2 Important Notice This Presentation contains forward-looking statements concerning the business, operations and financial performance and condition of Satsuma Pharmaceuticals, Inc. (the “Company”), as well as the Company’s plans, objectives
March 1, 2021	EX-10.1	Securities Purchase Agreement, dated February 26, 2021 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 1, 2021). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of February 26, 2021 by and among Satsuma Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and the Investors identified on Exhibit A attached hereto (each an ?Investor? and collectively the ?Investors?). RECITALS A. The Company and the Investors are executing a
March 1, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events 8-K 1 d136544d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2021 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other juri
February 16, 2021	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 tm214737d13ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G/A filed herewith (and any amendments thereto), relating to the common stock of Satsuma Pharmaceuticals, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchang
February 16, 2021	SC 13G/A	December 31, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 80405P107 (CUSIP Number) December 31, 2020 Date of Event Which Requires Filing of the Statement Check the appropriate
December 4, 2020	EX-99.1	AGREEMENT REGARDING JOINT FILING OF SCHEDULE 13G EX-99.1 Exhibit 1 AGREEMENT REGARDING JOINT FILING OF SCHEDULE 13G Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of securities of the Issuer. Date: December 4, 2020 OSAGE UNIVERSITY PARTNERS III, LP
December 4, 2020	SC 13G/A	STSA / Sterling Financial Corp / Osage University Partners III, LP - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1) Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 80405P107 (CUSIP Number) September 11, 2020
November 10, 2020	EX-99.1	Satsuma Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results EX-99.1 Exhibit 99.1 Satsuma Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results - Analysis of results from EMERGE™ Phase 3 efficacy trial of STS101 ongoing; expect to communicate next steps by early 2021 - Cash, cash equivalents and marketable securities of $82.1 million as of September 30, 2020; based on current operating plans, expected to provide runway th
November 10, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d947405d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other juri
November 10, 2020	CORRESP	- CORRESP Satsuma Pharmaceuticals, Inc. 400 Oyster Point Boulevard, Suite 221 South San Francisco, CA 94080 November 10, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Ada D. Sarmento Re: Satsuma Pharmaceuticals, Inc. Registration Statement on Form S-3 (Registration No. 333-249645) Ladies and Gentlemen: In accordan
November 10, 2020	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 10-Q 1 stsa-10q20200930.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi
October 23, 2020	EX-1.2	Sales Agreement, dated October 23, 2020, by and between Satsuma Pharmaceuticals, Inc. and SVB Leerink LLC. EX-1.2 Exhibit 1.2 SATSUMA PHARMACEUTICALS, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT October 23, 2020 SVB LEERINK LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Satsuma Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC (the “Agent”), as follows: 1
October 23, 2020	S-3	- REGISTRATION STATEMENT ON FORM S-3 Registration Statement on Form S-3 Table of Contents AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 23, 2020 Registration No.
October 23, 2020	EX-4.4	Form of Indenture. EX-4.4 Exhibit 4.4 SATSUMA PHARMACEUTICALS, INC. INDENTURE Dated as of , 20 [ ], as Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 6 Section 2.1. Issuable in Series 6 Sect
October 9, 2020	SC 13G/A	STSA / Sterling Financial Corp / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 80405P107 (CUSIP Number) September 30, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh
September 10, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2020 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (C
August 11, 2020	EX-10.7	Fourth Amendment to the Amended and Restated Licensing Assignment Agreement, dated May 25, 2020, by and between Satsuma Pharmaceuticals, Inc. and Shin Nippon Biomedical Laboratories, Ltd. Exhibit 10.7 AMENDMENT NO.4 TO LICENSING AND ASSIGNMENT AGREEMENT This Amendment No.4 (“Amendment No.4”) to the Licensing and Assignment Agreement by and between Satsuma Pharmaceuticals, Inc. (“Company”) and Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) of June 30, 2016 (the “Agreement”) is dated as of May 25, 2020 (“Amendment No.4 Effective Date”). A. Company and SNBL have previously entered
August 11, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation) (Comm
August 11, 2020	10-Q	Quarterly Report - 10-Q 10-Q 1 stsa-10q20200630.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission Fi
August 11, 2020	EX-99.1	Satsuma Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results Completed treatment phase of pivotal EMERGE™ Phase 3 efficacy trial of STS101 as planned and remain on track to report top-line results in late Septemb EX-99.1 Exhibit 99.1 Satsuma Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results Completed treatment phase of pivotal EMERGE™ Phase 3 efficacy trial of STS101 as planned and remain on track to report top-line results in late September or early October 2020 Initiated patient enrollment in ASCEND™ Phase 3 open-label safety trial of STS101 Cash, cash equivalents
August 10, 2020	SC 13G/A	STSA / Sterling Financial Corp / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 80405P107 (CUSIP Number) July 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t
July 7, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 d34971d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2020 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdicti
June 15, 2020	8-K	Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2020 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation
May 12, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2020 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation)
May 12, 2020	EX-99.1	Satsuma Pharmaceuticals Reports First Quarter 2020 Financial and Business Results STS101 EMERGE™ Phase 3 efficacy trial remains on track with announcement of topline data expected in second half of 2020 Company well-capitalized with cash, cash equiva EX-99.1 2 d914757dex991.htm EX-99.1 Exhibit 99.1 Satsuma Pharmaceuticals Reports First Quarter 2020 Financial and Business Results STS101 EMERGE™ Phase 3 efficacy trial remains on track with announcement of topline data expected in second half of 2020 Company well-capitalized with cash, cash equivalents, and marketable securities of $104.1 million at the end of Q1 2020, providing runway through pl
May 12, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39041 Satsuma Pharmaceuticals, Inc.
April 24, 2020	DEFA14A	- NOTICE & ACCESS Notice & Access UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini
April 24, 2020	DEF 14A	Definitive Proxy Statement DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 10, 2020	S-8	STSA / Sterling Financial Corp S-8 - - REGISTRATION STATEMENT ON FORM S-8 Registration Statement on Form S-8 As filed with the Securities and Exchange Commission on March 10, 2020 Registration No.
March 10, 2020	10-K	STSA / Sterling Financial Corp 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39041 Satsuma Pharmaceuticals, Inc.
March 10, 2020	EX-4.6	Description of Capital Stock Exhibit 4.6 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes our capital stock and the material provisions of our amended and restated certificate of incorporation and our amended and restated bylaws, the amended and restated investors’ rights agreement to which we and certain of our stockholders are par
March 10, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2020 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporatio
March 10, 2020	EX-99.1	Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Results On track to announce topline data in second half of 2020 from Phase 3 EMERGE™ efficacy trial evaluating STS101 for the acute treatment of EX-99.1 Exhibit 99.1 Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Results On track to announce topline data in second half of 2020 from Phase 3 EMERGE efficacy trial evaluating STS101 for the acute treatment of migraine Company well-capitalized with cash, cash equivalents, and marketable securities of $117.9 million at the end of 2019, pr
February 14, 2020	SC 13G/A	80405P107 / Satsuma Pharmaceuticals Inc / CITADEL ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 80405P107 (CUSIP Number) December 31, 2019 Date of Event Which
February 14, 2020	SC 13G/A	80405P107 / Satsuma Pharmaceuticals Inc / CAXTON CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 13, 2020	SC 13G	80405P107 / Satsuma Pharmaceuticals Inc / TPG Group Holdings (SBS) Advisors, Inc. - ACQUISITION OF BENEFICIAL OWNERSHIP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. )* Under the Securities Exchange Act of 1934 Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Titles of Class of Securities) 80405P107 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
January 27, 2020	SC 13G/A	STSA / Sterling Financial Corp / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 80405P107 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropri
November 27, 2019	SC 13G	STSA / Sterling Financial Corp / Osage University Partners Iii, Lp - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. ) Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 80405P107 (CUSIP Number) September 17, 2019 (D
November 27, 2019	EX-99.1	AGREEMENT REGARDING JOINT FILING OF SCHEDULE 13G EX-99.1 Exhibit 1 AGREEMENT REGARDING JOINT FILING OF SCHEDULE 13G Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of securities of the Issuer. Date: November 27, 2019 OSAGE UNIVERSITY PARTNERS III, L
November 12, 2019	10-Q	STSA / Sterling Financial Corp 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39041 Satsuma Pharmaceuticals, Inc.
November 12, 2019	EX-99.1	Satsuma Pharmaceuticals Reports Third Quarter 2019 Financial and Business Results Completed upsized initial public offering of $90.8 million in gross proceeds Dosed first patient in Phase 3 EMERGE™ efficacy trial of STS101 for the acute treatment of EX-99.1 Exhibit 99.1 Satsuma Pharmaceuticals Reports Third Quarter 2019 Financial and Business Results Completed upsized initial public offering of $90.8 million in gross proceeds Dosed first patient in Phase 3 EMERGE™ efficacy trial of STS101 for the acute treatment of migraine Presented STS101 Phase 1 trial results and other STS101 data at medical meetings South San Francisco, CA, November 12, 2
November 12, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorporation)
October 21, 2019	SC 13G	STSA / Sterling Financial Corp / CAXTON CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
October 10, 2019	SC 13G	STSA / Sterling Financial Corp / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 80405P107 (CUSIP Number) September 30, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic
September 23, 2019	SC 13G	STSA / Sterling Financial Corp / CITADEL ADVISORS LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 80405P107 (CUSIP Number) September 13, 2019 Date of Event Which
September 23, 2019	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 tv529736ex99-1.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Satsuma Pharmaceuticals, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Ex
September 17, 2019	S-8	STSA / Sterling Financial Corp S-8 - - REGISTRATION STATEMENT ON FORM S-8 Registration Statement on Form S-8 As filed with the Securities and Exchange Commission on September 17, 2019 Registration No.
September 17, 2019	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2019 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39041 81-3039831 (State or other jurisdiction of incorpor
September 17, 2019	EX-3.2	Amended and Restated Bylaws. EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF SATSUMA PHARMACEUTICALS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE
September 17, 2019	EX-3.1	Amended and Restated Certificate of Incorporation. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SATSUMA PHARMACEUTICALS, INC. Satsuma Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is Satsuma Pharmaceuticals, Inc. The Corporation’s original Certificate of Incorporation was filed with the Secretary of S
September 17, 2019	EX-99.1	Satsuma Pharmaceuticals, Inc. Announces Closing of Initial Public Offering EX-99.1 Exhibit 99.1 Satsuma Pharmaceuticals, Inc. Satsuma Pharmaceuticals, Inc. Announces Closing of Initial Public Offering South San Francisco, California, September 17, 2019 — Satsuma Pharmaceuticals, Inc. (“Satsuma” or the “Company”) (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today an
September 17, 2019	SC 13D	STSA / Sterling Financial Corp / RA Capital Management, LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response… 10.4 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Satsuma Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 80405P107 (CUSIP Number
September 17, 2019	EX-99.1	Exhibit 1 Joint Filing Agreement by and among the Reporting Persons. CUSIP No. 80405P107 Exhibit 1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of September 17, 2019, is by and among RA Capital Management, LLC and Peter Kolchinsky (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or 13D with respect
September 13, 2019	424B4	5,500,000 Shares Common Stock Prospectus Filed Pursuant to Rule 424(b)(4) Table of Contents Index to Financial Statements Filed purusant to Rule 424(b)(4) Registration No.
September 13, 2019	S-1MEF	STSA / Sterling Financial Corp S-1MEF - - S-1MEF S-1MEF 1 d798440ds1mef.htm S-1MEF As filed with the Securities and Exchange Commission on September 12, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SATSUMA PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 81-3039831 (State or other jurisd
September 11, 2019	S-1/A	Form S-1 S-1/A 1 d764780ds1a.htm AMENDMENT NO. 2 TO FORM S-1 Table of Contents Index to Financial Statements As filed with the Securities and Exchange Commission on September 11, 2019. Registration No. 333-233347 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Satsuma Pharmaceuticals, Inc. (Exact nam
September 11, 2019	EX-3.2	Amended and Restated Certificate of Incorporation, effecting a stock split, currently in effect. EX-3.2 2 d764780dex32.htm EX-3.2 Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SATSUMA PHARMACEUTICALS, INC. Satsuma Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is Satsuma Pharmaceuticals, Inc. The Corporation’s original Certificate of Incorporation was fil
September 10, 2019	8-A12B	Form 8-A 8-A12B 1 d801881d8a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 SATSUMA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 81-3039831 (State of incorporation or organization) (I.R.S. Employe
September 10, 2019	CORRESP	STSA / Sterling Financial Corp CORRESP - - Underwriters' Acceleration Request September 10, 2019 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
September 10, 2019	CORRESP	STSA / Sterling Financial Corp CORRESP - - Company Acceleration Request Satsuma Pharmaceuticals, Inc. 400 Oyster Point Boulevard, Suite 221 South San Francisco, CA 94080 September 10, 2019 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Mark Brunhofer, Senior Accounting Examiner Jim Rosenberg, Sen
September 3, 2019	EX-10.12	Form Change in Control and Severance Agreement. Exhibit 10.12 SATSUMA PHARMACEUTICALS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between [ ] (“Executive”) and Satsuma Pharmaceuticals, Inc. (the “Company”), effective as of [the latest date set forth by the signatures of the parties hereto below]/[the date Executive commences employment with the
September 3, 2019	EX-10.10	Non-Employee Director Compensation Program. Exhibit 10.10 SATSUMA PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of Satsuma Pharmaceuticals, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shal
September 3, 2019	EX-3.2	Form of Amended and Restated Certificate of Incorporation, effecting a stock split, to be in effect prior to the effectiveness of this registration statement. Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SATSUMA PHARMACEUTICALS, INC. Satsuma Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is Satsuma Pharmaceuticals, Inc. The Corporation’s original Certificate of Incorporation was filed with the Secretary of State of
September 3, 2019	EX-4.2	Form of Common Stock Certificate. Exhibit 4.2 INCORPORATED OF THE STATE UNDER OF DELAWARE THE LAWS SATSUMA PHARMACEUTICALS, INC. CUSIP 80405P 10 7 CERTAIN SEE REVERSE DEFINITIONS FOR THIS CERTIFIES THAT IS THE RECORD HOLDER OF FULLY PAID AND NON-ASSESSABLE SATSUMA SHARES PHARMACEUTICALS, OF COMMON STOCK, $0.0001 INC. PAR VALUE PER SHARE, OF transferable on the books of the Corporation in person or by duly authorized attorney upon
September 3, 2019	S-1/A	As filed with the Securities and Exchange Commission on September 3, 2019. S-1/A 1 d764780ds1a.htm AMENDMENT NO. 1 TO FORM S-1 Table of Contents Index to Financial Statements As filed with the Securities and Exchange Commission on September 3, 2019. Registration No. 333-233347 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Satsuma Pharmaceuticals, Inc. (Exact name
September 3, 2019	EX-10.5(A)	2019 Incentive Award Plan Exhibit 10.5(a) SATSUMA PHARMACEUTICALS, INC. 2019 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. ARTICLE II. DEFINITIONS As used in the Plan, the following words and phr
September 3, 2019	CORRESP	STSA / Sterling Financial Corp CORRESP - - CORRESP 1 filename1.htm 140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris Dubai Riyadh Düsseldorf San Diego September 3, 2019 Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Houston Silicon Valley London Singapore Los Angeles Toky
September 3, 2019	EX-10.6	2019 Employee Stock Purchase Plan. Exhibit 10.6 SATSUMA PHARMACEUTICALS, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The Plan’s purpose is to assist employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company pursuant to a plan which is intended to qualify as an “employee stock purchase plan” under Section 423 of the Code, and to help such employees provide for their
September 3, 2019	EX-1.1	Form of Underwriting Agreement. Exhibit 1.1 [•] SATSUMA PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENT [•], 2019 CREDIT SUISSE SECURITIES (USA) LLC SVB LEERINK LLC EVERCORE GROUP L.L.C. As Representatives of the Several Underwriters c/o Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, New York 10010 c/o SVB Leerink LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 c/o Evercore Grou
August 27, 2019	CORRESP	STSA / Sterling Financial Corp CORRESP - - CORRESP 140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES Abu Dhabi Milan Barcelona Moscow Beijing Munich Boston New Jersey Brussels New York Century City Orange County Chicago Paris August 27, 2019 Dubai Riyadh Düsseldorf Rome Frankfurt San Diego Hamburg San Francisco Hong Kong Shanghai Houston Silicon Valley London Singapor
August 16, 2019	EX-3.1	Amended and Restated Certificate of Incorporation. EX-3.1 2 d764780dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SATSUMA PHARMACEUTICALS, INC. Satsuma Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is Satsuma Pharmaceuticals, Inc. The Corporation’s original Certificate of Incorporation was fil
August 16, 2019	EX-10.2(B)	First Amendment to Amended and Restated Licensing and Assignment Agreement, dated January 13, 2017, by and between Satsuma Pharmaceuticals, Inc. and Shin Nippon Biomedical Laboratories, Ltd. Exhibit 10.2(b) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. AMENDMENT NO. l TO LICENSING AND ASSIGNMENT AGREEMENT This Amendment No. l (“Amendment No. l”) to the Licensing and Assignment Agreement by and between Sat
August 16, 2019	EX-10.2(C)	Second Amendment to Amended and Restated Licensing and Assignment Agreement, dated as of April 27, 2017, by and between Satsuma Pharmaceuticals, Inc. and Shin Nippon Biomedical Laboratories, Ltd. Exhibit 10.2(c) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. AMENDMENT NO. 2 TO LICENSING AND ASSIGNMENT AGREEMENT This Amendment No. 2 (“Amendment No. 2”) to the Licensing and Assignment Agreement by and between Sat
August 16, 2019	EX-10.2(D)	Third Amendment to the Amended and Restated Licensing and Assignment Agreement, dated October 6, 2017, by and between Satsuma Pharmaceuticals, Inc. and Shin Nippon Biomedical Laboratories, Ltd. Exhibit 10.2(d) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. AMENDMENT NO. 3 TO LICENSING AND ASSIGNMENT AGREEMENT This Amendment No. 3 (“Amendment No. 3”) to LICENSING AND ASSIGNMENT AGREEMENT, made and entered into
August 16, 2019	EX-10.5(B)	Form of Stock Option Grant Notice and Stock Option Agreement under the 2019 Incentive Award Plan. Exhibit 10.5(b) SATSUMA PHARMACEUTICALS, INC. 2019 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Satsuma Pharmaceuticals, Inc., a Delaware corporation, (the “Company”), pursuant to its 2019 Incentive Award Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), an option to purchase the number of shares of the Company’s Common Stock (the “
August 16, 2019	EX-10.8	Offer Letter, dated June 12, 2017, by and between Satsuma Pharmaceuticals, Inc. and Detlef Albrecht. Exhibit 10.8 Satsuma Pharmaceuticals, Inc. June 12, 2017 Detlef F. Albrecht, M.D. *** Dear Detlef: I am pleased to offer you a position with Satsuma Pharmaceuticals, Inc. (the “Company”), as its Chief Medical Officer (“CMO”) reporting to the Company’s President and Chief Executive Officer (the “CEO”). Unless otherwise defined in the letter, capitalized terms will have the meanings set forth in App
August 16, 2019	EX-10.5(A)	2019 Incentive Award Plan. Exhibit 10.5(a) SATSUMA PHARMACEUTICALS, INC. 2019 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. ARTICLE II. DEFINITIONS As used in the Plan, the following words and phr
August 16, 2019	S-1	Power of Attorney. S-1 1 d764780ds1.htm S-1 Table of Contents Index to Financial Statements As filed with the Securities and Exchange Commission on August 16, 2019. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Satsuma Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware (
August 16, 2019	EX-10.7(B)	First Amendment to Offer Letter, dated June 17, 2016, by and between Satsuma Pharmaceuticals, Inc. and John Kollins. Exhibit 10.7(b) Amendment to Offer Letter This Amendment to the Offer Letter from Satsuma Pharmaceuticals, Inc. (the “Company”) to John A. Kollins dated as of June 17, 2016 (this “Amendment”), is effective upon the Closing of the Qualified Financing of the Company (as defined herein) (the “Effective Date”). In consideration of these promises and for other good and valuable consideration, the recei
August 16, 2019	EX-10.4(B)	Form of Stock Option Agreement under 2016 Equity Incentive Plan. Exhibit 10.4(b) SATSUMA PHARMACEUTICALS, INC. 2016 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the 2016 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement (the “Option Agreement”). I. NOTICE OF STOCK OPTION GRANT Name: «Name» Address: «Address» «CityStateZip» The undersigned Participant has b
August 16, 2019	EX-10.5(C)	Form of Restricted Stock Award Grant Notice under the 2019 Incentive Award Plan. Exhibit 10.5(c) SATSUMA PHARMACEUTICALS, INC. 2019 INCENTIVE AWARD PLAN RESTRICTED STOCK AWARD GRANT NOTICE Satsuma Pharmaceuticals, Inc., a Delaware corporation, (the “Company”), pursuant to its 2019 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”) the number of shares of the Company’s Common Stock set forth below (the “
August 16, 2019	EX-10.5(D)	Form of Restricted Stock Unit Award Grant Notice under the 2019 Incentive Award Plan. Exhibit 10.5(d) SATSUMA PHARMACEUTICALS, INC. 2019 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Satsuma Pharmaceuticals, Inc., a Delaware corporation, (the “Company”), pursuant to its 2019 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”), an award of restricted stock units (“Restricted Stock Units” or “RS
August 16, 2019	EX-4.5	Warrant by and between Satsuma Pharmaceuticals, Inc. and Life Science Loans II, LLC. EX-4.5 8 d764780dex45.htm EX-4.5 Exhibit 4.5 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF
August 16, 2019	EX-10.6	2019 Employee Stock Purchase Plan. Exhibit 10.6 SATSUMA PHARMACEUTICALS, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The Plan’s purpose is to assist employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company pursuant to a plan which is intended to qualify as an “employee stock purchase plan” under Section 423 of the Code, and to help such employees provide for their
August 16, 2019	EX-4.3	Amended and Restated Investors’ Rights Agreement, dated as of April 23, 2019, by and among Satsuma Pharmaceuticals, Inc. and the investors party thereto. Exhibit 4.3 SATSUMA PHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT April 23, 2019 TABLE OF CONTENTS Page Section 1 Definitions 1 1.1 Certain Definitions 1 Section 2 Registration Rights 4 2.1 Requested Registration 4 2.2 Company Registration 6 2.3 Registration on Form S-3 7 2.4 Expenses of Registration 7 2.5 Registration Procedures 8 2.6 Indemnification 9 2.7 Information by
August 16, 2019	EX-10.1	Lease Agreement, dated January 9, 2018, by and between Satsuma Pharmaceuticals, Inc. and Kashiwa Fudosan America, Inc. EX-10.1 9 d764780dex101.htm EX-10.1 Exhibit 10.1 O Y S T E R P O I N T M A R I N A P L A Z A Office Lease of SUITE 221 to SATSUMA PHARMACEUTICALS, INC., a Delaware corporation 400 Oyster Point Boulevard South San Francisco, CA 94080 Exhibit 10.1 OYSTER POINT MARINA PLAZA Office Lease of SUITE 221 to SATSUMA PHARMACEUTICALS, INC., a Delaware corporation 400 Oyster Point Boulevard South San Francisc
August 16, 2019	CORRESP	STSA / Sterling Financial Corp CORRESP - - CORRESP 140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris August 16, 2019 Dubai Riyadh Düsseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Houston Silicon Valley London Singapore Los Angeles Tokyo Madrid Washingto
August 16, 2019	EX-10.7(A)	Offer Letter, dated June 17, 2016, by and between Satsuma Pharmaceuticals, Inc. and John Kollins. Exhibit 10.7(a) Satsuma Pharmaceuticals, Inc. June 17th, 2016 John A. Kollins *** Dear John: I am pleased to offer you a position with Satsuma Pharmaceuticals, Inc. (the “Company”), as its Chief Executive Officer reporting to the Company’s Board of Directors (the “Board”). Unless otherwise defined in the letter, capitalized terms will have the meanings set forth in Appendix A. If you accept our of
August 16, 2019	EX-3.5	Amended and Restated Bylaws. Exhibit 3.5 AMENDED AND RESTATED BYLAWS OF SATSUMA PHARMACEUTICALS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDU
August 16, 2019	EX-10.9	Offer Letter, dated December 21, 2018, by and between Satsuma Pharmaceuticals, Inc. and Tom O’Neil. EX-10.9 25 d764780dex109.htm EX-10.9 Exhibit 10.9 Satsuma Pharmaceuticals, Inc. December 21, 2018 Tom O’Neil *** Via Electronic Mail Dear Tom: I am pleased to offer you a position with Satsuma Pharmaceuticals, Inc. (the “Company”), as its Chief Financial Officer reporting to the Company’s President and Chief Executive Officer (the “CEO”). Unless otherwise defined in the letter, capitalized terms w
August 16, 2019	EX-3.3	Form of Amended and Restated Certificate of Incorporation, to be in effect immediately prior to the consummation of this offering. Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SATSUMA PHARMACEUTICALS, INC. Satsuma Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is Satsuma Pharmaceuticals, Inc. The Corporation’s original Certificate of Incorporation was filed with the Secretary of State of
August 16, 2019	EX-10.11	Form of Indemnification Agreement for Directors and Officers Exhibit 10.11 SATSUMA PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is effective as of «Date» by and between Satsuma Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and «Indemnitee» (“Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and the Indemnitee covering indemnification.
August 16, 2019	EX-10.4(A)	2016 Equity Incentive Plan. Exhibit 10.4(a) SATSUMA PHARMACEUTICALS, INC. 2016 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits the grant of Incentive St
August 16, 2019	EX-10.2(A)	Amended and Restated Licensing and Assignment Agreement, dated December 16, 2016, by and between Satsuma Pharmaceuticals, Inc. and Shin Nippon Biomedical Laboratories, Ltd. EX-10.2(A) 10 d764780dex102a.htm EX-10.2(A) Exhibit 10.2(a) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. EXECUTION VERSION LICENSING AND ASSIGNMENT AGREEMENT THIS LICENSING AND ASSIGNMENT AGREEMENT (this “Agreement”)
August 16, 2019	EX-3.4	Amended and Restated Bylaws. Exhibit 3.4 BYLAWS OF SATSUMA PHARMACEUTICALS, INC. Amended and Restated December 16, 2016 TABLE OF CONTENTS Page ARTICLE I — MEETINGS OF STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meeting 1 1.4 Notice of Stockholders’ Meetings 1 1.5 Quorum 2 1.6 Adjourned Meeting; Notice 2 1.7 Conduct of Business 2 1.8 Voting 2 1.9 Stockholder Action by Written Consent Without a Meeti
August 16, 2019	EX-4.4	Warrant by and between Satsuma Pharmaceuticals, Inc. and Silicon Valley Bank. Exhibit 4.4 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN
August 16, 2019	EX-10.3	Loan and Security Agreement, dated as of October 26, 2018, by and between Silicon Valley Bank and the Company. Exhibit 10.3 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of October 26, 2018 (the “Effective Date”) by and between SILICON VALLEY BANK, a California corporation (“Bank”), and SATSUMA PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as foll
August 2, 2019	EX-3.4	BYLAWS OF SATSUMA PHARMACEUTICALS, INC. Amended and Restated December 16, 2016 Exhibit 3.4 BYLAWS OF SATSUMA PHARMACEUTICALS, INC. Amended and Restated December 16, 2016 TABLE OF CONTENTS Page ARTICLE I — MEETINGS OF STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meeting 1 1.4 Notice of Stockholders’ Meetings 1 1.5 Quorum 2 1.6 Adjourned Meeting; Notice 2 1.7 Conduct of Business 2 1.8 Voting 2 1.9 Stockholder Action by Written Consent Without a Meeti
August 2, 2019	EX-10.7(B)	Amendment to Offer Letter Exhibit 10.7.b Amendment to Offer Letter This Amendment to the Offer Letter from Satsuma Pharmaceuticals, Inc. (the “Company”) to John A. Kollins dated as of June 17, 2016 (this “Amendment”), is effective upon the Closing of the Qualified Financing of the Company (as defined herein) (the “Effective Date”). In consideration of these promises and for other good and valuable consideration, the receip
August 2, 2019	DRS/A	Confidential Draft Submission No. 2 submitted to the Securities and Exchange Commission on August 2, 2019. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information contained herein DRS/A 1 filename1.htm Table of Contents Index to Financial Statements Confidential Draft Submission No. 2 submitted to the Securities and Exchange Commission on August 2, 2019. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information contained herein remains confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANG
August 2, 2019	EX-10.2(B)	AMENDMENT NO. l TO LICENSING AND ASSIGNMENT AGREEMENT Exhibit 10.2(b) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. AMENDMENT NO. l TO LICENSING AND ASSIGNMENT AGREEMENT This Amendment No. l (“Amendment No. l”) to the Licensing and Assignment Agreement by and between Sat
August 2, 2019	EX-10.8	Satsuma Pharmaceuticals, Inc. June 12, 2017 Exhibit 10.8 Satsuma Pharmaceuticals, Inc. June 12, 2017 Detlef F. Albrecht, M.D. *** Dear Detlef: I am pleased to offer you a position with Satsuma Pharmaceuticals, Inc. (the “Company”), as its Chief Medical Officer (“CMO”) reporting to the Company’s President and Chief Executive Officer (the “CEO”). Unless otherwise defined in the letter, capitalized terms will have the meanings set forth in App
August 2, 2019	EX-3.5	AMENDED AND RESTATED BYLAWS OF SATSUMA PHARMACEUTICALS, INC. (a Delaware corporation) Exhibit 3.5 AMENDED AND RESTATED BYLAWS OF SATSUMA PHARMACEUTICALS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDU
August 2, 2019	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SATSUMA PHARMACEUTICALS, INC. EX-3.1 2 filename2.htm Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SATSUMA PHARMACEUTICALS, INC. Satsuma Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is Satsuma Pharmaceuticals, Inc. The Corporation’s original Certificate of Incorporation was filed with th
August 2, 2019	EX-10.2(C)	AMENDMENT NO. 2 TO LICENSING AND ASSIGNMENT AGREEMENT EX-10.2(C) 9 filename9.htm Exhibit 10.2(c) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. AMENDMENT NO. 2 TO LICENSING AND ASSIGNMENT AGREEMENT This Amendment No. 2 (“Amendment No. 2”) to the Licensing and Assignment A

STSA / Satsuma Pharmaceuticals Inc - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)